We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JNJ:NYSEJohnson & Johnson Analysis

Data as of 2026-09-10 - not real-time

$267.08

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

At $267.08, Johnson & Johnson shows a bullish moving-average alignment, with shorter averages sitting above longer ones. RSI sits at 50.3, which reads as neutral, and MACD momentum is bearish. The recent range runs from support at $255.26 up to resistance at $281.07.
Multiples put this in overvalued territory: 31.2 times earnings against the sector's 29.8. Analyst price targets sit 3.2% above the current price. Revenue is growing at 6.6% on a 21.5% profit margin. The 1.99% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 22.4%, a beta of -0.18 and a maximum drawdown of 11.0%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 3/10 conviction over the longer horizon.

Top Market Events

Chris Lange Tue, September 8, 2026 at 12:40 PM UTC 0 PeopleImages / Getty Images Quick Read - PepsiCo's 4% yield and...Johnson & Johnson stock trades near $268 after IMAAVY won U.Johnson & Johnson JNJ is back in focus after its stock moved higher following a 6.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 236.49
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 31.2 versus sector average of 29.8
  • Trading above the 200-day average of 236.49

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • P/E of 31.2 versus sector average of 29.8
  • Profit margin of 21.5% is healthy
  • Return on equity of 25.7%

Key Metrics & Analysis

Financial Health

Revenue Growth6.60%
Profit Margin21.48%
P/E Ratio31.2
ROE25.74%
ROA8.60%
Debt/Equity57.71
P/B Ratio7.6
Op. Cash Flow$27.6B
Free Cash Flow$16.9B
Industry P/E29.8

Technical Analysis

TrendBullish
RSI50.3
Support$255.26
Resistance$281.07
MA 20$268.99
MA 50$262.23
MA 200$236.49
MACDBearish
VolumeIncreasing
Fear & Greed Index92.02

Valuation

Fair Value$105.21
Target Price$275.64
Upside/Downside3.20%
GradeOvervalued
TypeGrowth
Dividend Yield1.99%

Risk Assessment

Beta-0.18
Volatility22.44%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.